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Abstract
Compared to other malignancies, there is a lack of easy-to-evaluate biomarkers for gastric cancer, which is associated
with an adverse clinical outcome in many cases. Here, we present Stroma AReactive Invasion Front Areas (SARIFA) as a
new histological prognostic marker. We defined SARIFA as the direct contact between a cluster of tumor glands/cells
comprising at least five tumor cells and inconspicuous surrounding adipose tissue at the invasion front. A total of
480 adenocarcinomas of the stomach and the gastroesophageal junction from two different collections were classified
according to SARIFA. To understand the potential underlying mechanisms, a transcriptome analysis was conducted
using digital spatial profiling (DSP). It was found that 20% of the tumors were SARIFA-positive. Kappa values between
the three pathologists were good in both collections: 0.74 and 0.78. Patients who presented SARIFA-positive tumors
had a significantly lower overall survival in Collections A (median: 20.0 versus 44.0 months; p = 0.014, n = 160)
and B (median: 15.0 versus 41.0 months; p < 0.0001, n = 320). SARIFA positivity emerged as a negative independent
prognostic factor for overall survival (HR 1.638, 95% CI 1.153–2.326, p = 0.006). Using DSP, the most upregulated
genes in SARIFA-positive cases were those associated with triglyceride catabolism and endogenous sterols. COL15A1,
FABP2, and FABP4were differentially expressed in positive cases. At the protein level, the expression of proteins related
to lipidmetabolismwas confirmed. SARIFA combines low inter-observer variability, minimal effort, and high prognostic
relevance, and is therefore an extremely promising biomarker related to tumor-promoting adipocytes in gastric cancer.
©2021 The Authors. The Journal of Pathology published by JohnWiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain
and Ireland.
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Introduction
Gastric cancer is ranked as the sixth most common can-
cer entity worldwide, having accounted for approxi-
mately 780 000 cancer-associated deaths in 2018 [1].
So far, the best parameter for predicting prognosis, and
therefore therapy, in gastric cancer patients is TNM stag-
ing. The factors that are relevant for determining the
prognosis of gastric carcinomas are local infiltration
depth, locoregional lymph node involvement, distant
metastases, and vascular invasion [2–4]. Additionally,
diffuse Laurén subtype and proximal tumor localization
are also known negative prognostic factors for gastric
cancer [5–7]. The introduction of perioperative
chemotherapy after 2005 has improved the outcome in
stage 2 and 3 gastric cancers, with a median survival of
50 months versus 34 months [8]. However, the progno-
sis of gastric cancer is still poor and has a 5-year survival
rate that has not changed during the period between 2000
and 2014, with survival rates being between 31.4% and
33.5% in Germany [9]. To improve the prognosis esti-
mation in gastric cancer beyond TNM staging,
histomorphology-based concepts, such as tumor bud-
ding and the tumor–stroma ratio (TSR), have already
been investigated. Unlike the case of colorectal cancer,
such biomarkers have not reached general acceptance
or been recommended in routine diagnostics [10–12].
Moreover, the molecular classification of the Cancer
Genome Atlas (TCGA) identified distinct subgroups of
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gastric carcinomas that were associated with specific
clinicopathological characteristics, but they failed to
robustly predict patient survival [13]. So far, only micro-
satellite instability (MSI) and programmed death-ligand
1 (PD-L1) status have gained acceptance as prognostic
biomarkers in gastric cancer [14]. Therefore, there is still
a need to identify biomarkers for improving the prognos-
tic prediction and therapy stratification in gastric cancer.
During our investigations addressing the prognostic
value of the TSR in colon cancer, we recognized that in
a certain portion of cases the tumor formations come into
direct contact with adipose cells that lack a stromal reac-
tion. Quite recently, we were able to confirm our hypoth-
esis that this morphological feature, which we referred to
as Stroma AReactive Invasion Front Areas (SARIFA),
can serve as an adverse prognostic factor for the outcome
in colon cancer [15]. The advantage of this biomarker is
its simplicity; it does not need any additional testing or
expenditure, offers ease of learning, has minimal time
requirements, and provides extraordinarily low inter-
observer variability. The identification of this phenome-
non in colon cancer gave rise to the question of whether
this occurs in other cancer entities as well. The fact that
SARIFA represents the areas in which there is direct con-
tact between the tumor cells and the local mesenchymal
tissue without intervening reactive collagen raises the
question of whether this enables an interaction that has
tumor-promoting effects. Considering the observation
that obesity is associated with an increased incidence
and aggressivity of malignant tumors, there is increasing
interest in the crosstalk between the tumor cells and adi-
pocytes. Indeed, the experimental data indicate that
tumors gain advantages from a direct interaction with adi-
pocytes [16].
The aim of the present study was to investigate the
prognostic significance of SARIFA in a limited test col-
lection of adenocarcinomas of the stomach and the gas-
troesophageal junction (n = 160) and to further
validate the results in a larger collection of 320 patients.
In addition, the possible underlying mechanisms or dif-
ferences between negative and positive cases were




Patient collection A served as the test collection and con-
sisted of surgical resection specimens from 160 patients
with adenocarcinomas of the stomach and the gastro-
esophageal junction (AEG II and III according to Sie-
wert and Stein [17]) that at least presented infiltration
of the submucosa (pT1b). These patients were treated
between 2005 and 2018 at the Department of Surgery
of the University Hospital Augsburg. In total, 69% of
the tumors had been treated with surgery alone and
31% of the patients received neoadjuvant chemotherapy
(CTx). Collection B was formed as the validation
collection and comprised 320 patients selected using
the same inclusion criteria as those used for Collection
A. Among these, 28% of the patients received neoadju-
vant CTx, and their detailed clinicopathological charac-
teristics have been summarized in Tables 1 and 2.
The response to preoperative CTx was determined his-
topathologically and classified into three tumor-regression
grades (TRGs) – TRG1b, TRG2, and TRG3 – which
corresponded to <10%, 10–50%, and >50% residual
tumor cells [18]. All patients were treated with chemother-
apeutic regimes based on platinum/5-fluorouracil (5-FU)
(Table 1). Further, all surgical approaches included an
abdominal D2 lymphadenectomy [19].
The follow-up data were obtained from the tumor data
management of the University Hospital of Augsburg, and
the median follow-up was calculated using the inverse
Kaplan–Meier method [20]. The primary endpoint of
the study was overall survival (OS), which was defined
as the time elapsed between the date of diagnosis and
the death of the patient due to any cause. Patients with
an OS of less than 30 days were excluded from the study.
The study was approved by the ethical committee of
the Ludwig Maximilian University of Munich (refer-
ence: 20-0922) and was performed in accordance with
the Declaration of Helsinki. According to the ethics vote
of the institutional review boards of the Ludwig Maxi-
milian University of Munich (reference: 20-0922), a
declaration of consent was not necessary.
Definition and assessment of SARIFA
SARIFA was evaluated based on entire slide sections
that covered about 220 mm2. We have defined SAR-
IFA as an area located at the invasion front (IF) in
which a tumor gland or a group of at least five tumor
cells directly approach adipocytes without separating
stroma. In addition, SARIFA was said to be present
when tumor cells were directly adjacent to local tissue,
such as the smooth muscle in muscularis propria, with-
out a stromal reaction, such as fibroblastic proliferation,
collagen formation, or a histiocytic reaction. We classi-
fied tumors that presented these characteristics as
SARIFA-positive and the others as SARIFA-negative.
Even if only a single SARIFA was present (e.g. a single
tumor gland surrounded directly by inconspicuous adi-
pose tissue), we classified the tumor as SARIFA-posi-
tive. The first (FA), third (TA), and last author
(LA) independently assessed all tumors. They did not
have access to each other’s results or the clinical data.
An exemplary tumor slide preselected by FA was used
for assessment in each case. Further, any discrepant
results were discussed using a multi-head microscope,
and a consensus was reached. Example images are pre-
sented in Figure 1.
Tissue microarray construction and TCGA
classification
For the classification according to the TCGA, tissue
microarrays (TMAs) were constructed. Tumors were
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classified in analogy to the TCGA classification [13]
based on the immunohistochemical expression of PMS2,
MSH6, E-cadherin, p53, and EBER-CISH [21,22]. The
TMA construction and classification according to the
TCGA are described in more detail in the Supplementary
materials and methods.
Table 1. Clinicopathological characteristics – Collection A.
Variable n = 160 SARIFA-positive (n = 24) SARIFA-negative (n = 136) P value
Median age (range), years 70.5 (30–95) 71 (40–87) 70.5 (30–95) 0.100
Median follow-up (95% CI), months 56.0 (44.8–67.2) 80.0 (NA) 54.0 (41.2–66.8) 0.462
Sex 0.549
Female 58 36% 10 42% 48 35%
Male 102 64% 14 58% 88 65%
T status <0.001
pT1/2 61 38% 1 4% 60 44%
pT3/4 99 62% 23 96% 76 56%
N status 0.088
Negative 58 36% 5 21% 53 39%
Positive 102 64% 19 79% 83 61%
Distant metastasis 0.009
No 83 52% 7 29% 76 56%
Yes 67 42% 16 67% 51 38%
NA 10 6% 1 4% 9 7%
Grading 0.682
Low grade 54 34% 7 29% 47 35%
High grade 104 65% 16 67% 88 65%
NA 2 1% 1 4% 1 1%
Vascular invasion 0.184
Negative 145 91% 20 83% 125 92%
Positive 15 9% 4 17% 11 8%
Lymphovascular invasion 0.047
Negative 108 68% 12 50% 96 71%
Positive 52 33% 12 50% 40 29%
Laurén classification 0.265
Intestinal 90 56% 11 46% 79 58%
Non-intestinal 70 44% 13 54% 57 42%
Localization 1.000
Proximal 40 25% 6 25% 34 25%
Non-proximal 120 75% 18 75% 102 75%
R status 0.389
R0 141 88% 20 83% 121 89%
R1 13 8% 3 13% 10 7%
Rx 6 4% 1 4% 5 4%
TCGA 0.218
EBV+ 12 8% 0 0% 12 9%
MMRD 18 11% 2 8% 16 12%
GS 35 22% 4 17% 31 23%
CIN 46 29% 10 42% 36 26%
Non-classifiable 40 25% 7 29% 33 24%
NA 9 6% 1 4% 8 6%
Death 0.006
No 81 51% 6 25% 75 55%
Yes 79 49% 18 75% 61 45%
nCTx 0.811
No 110 69% 17 71% 93 68%
Yes 50 31% 7 29% 43 32%
TRG 0.150
1b 5 10% 0 0% 5 12%
2 19 38% 1 14% 18 42%
3 26 52% 6 86% 20 47%
CTx regime 0.206
Cis/Ox/5-FU or Cap 13 26% 0 0% 13 30%
Ox +5-FU + Doc 19 38% 2 29% 17 40%
Cis + 5-FU + Epi 13 26% 4 57% 9 21%
Ox + Epi + Cap 4 8% 1 14% 3 7%
Others 1 2% 0 0% 1 2%
P values are shown for difference between SARIFA-positive and SARIFA-negative tumors; values in bold are statistically significant.
5-FU, 5-fluorouracil; Cap, capecitabine; CIN, chromosomally instable; Cis, cisplatin; Doc, docetaxel; EBV+, EBV positive; Epi, epirubicin; GS, genomically stable; MMRD,
mismatch repair deficient; nCTx, neoadjuvant CTx; Others, combination of Cis/Ox with other agents or crossover between different treatment regimens; Ox, oxaliplatin;
Pac, paclitaxel; TCGA, The Cancer Genome Atlas; TRG, tumor regression grade.
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NanoString GeoMx digital spatial profiling (DSP)
The DSP analysis is described in more detail in the Sup-
plementary materials and methods. Using DSP, we
performed a multiplexed and spatially resolved profiling
analysis on exemplary SARIFA-positive and SARIFA-
negative cases of TMAs (six SARIFA-positive and six
Table 2. Clinicopathological characteristics – Collection B.
Variable n = 320 SARIFA-positive (n = 72) SARIFA-negative (n = 248) P value
Median age (range), years 69.0 (36–91) 70.0 (38–91) 69.0 (36–90) 0.100
Median follow-up (95% CI), months 62.0 (49.6–74.4) 58.0 (26.5–89.5) 63.0 (49.0–77.0) 0.912
Sex 0.533
Female 103 32% 21 29% 82 33%
Male 217 68% 51 71% 166 67%
T status <0.001
pT1/2 92 29% 7 10% 85 34%
pT3/4 228 71% 65 90% 163 66%
N status 0.004
Negative 117 37% 16 22% 101 41%
Positive 203 63% 56 78% 147 59%
Distant metastasis <0.001
No 161 50% 23 32% 138 56%
Yes 136 43% 45 63% 91 37%
NA 23 7% 4 6% 19 8%
Grading 0.083
Low grade 105 33% 17 24% 88 35%
High grade 210 66% 52 72% 158 64%
NA 5 2% 3 4% 19 8%
Vascular invasion 0.017
Negative 258 81% 51 71% 207 83%
Positive 62 19% 21 29% 41 17%
Lymphovascular invasion 0.018
Negative 181 57% 32 44% 149 60%
Positive 139 43% 40 56% 99 40%
Laurén classification 0.648
Intestinal 172 54% 37 51% 135 54%
Non-intestinal 148 46% 35 49% 113 46%
Localization 0.087
Proximal 90 28% 26 36% 64 26%
Non-proximal 230 72% 46 64% 184 74%
R status 0.095
R0 265 83% 52 72% 213 86%
R1 42 13% 13 18% 29 12%
Rx 13 4% 7 10% 6 2%
TCGA 0.225
EBV+ 12 4% 4 6% 8 3%
MMRD 41 13% 7 10% 34 14%
GS 73 23% 12 17% 61 25%
CIN 95 30% 26 36% 69 28%
Non-classifiable 82 26% 20 28% 62 25%
NA 17 5% 3 4% 14 6%
Death 0.004
No 146 46% 22 31% 124 50%
Yes 174 54% 50 69% 124 50%
nCTx 0.503
No 230 72% 54 75% 176 71%
Yes 90 28% 18 25% 72 29%
TRG 0.143
1b 9 10% 0 0% 9 13%
2 22 24% 3 17% 19 26%
3 59 66% 15 83% 44 61%
CTx regime 0.505
Cis/Ox/5-FU or Cap 15 17% 2 11% 13 18%
Ox +5-FU + Doc 31 34% 6 33% 25 35%
Cis + 5-FU + Epi 31 34% 9 50% 22 31%
Ox + Epi + Cap 11 12% 1 6% 10 14%
Others 2 2% 0 0% 2 3%
P values are shown for difference between SARIFA-positive and SARIFA-negative tumors; values in bold are statistically significant.
5-FU, 5-fluorouracil; Cap, capecitabine; CIN, chromosomally instable; Cis, cisplatin; Doc, docetaxel; EBV+, EBV positive; Epi, epirubicin; GS, genomically stable; MMRD,
mismatch repair deficient; nCTx, neoadjuvant CTx; Others, combination of Cis/Ox with other agents or crossover between different treatment regimens; Ox, oxaliplatin;
Pac, paclitaxel; TCGA, The Cancer Genome Atlas; TRG, tumor regression grade.
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SARIFA-negative cases). DSP technology uses RNA
detection probes with ultraviolet (UV) photocleavable
indexing oligos for transcriptomic profiling within the
selected regions of interest (ROIs). As shown in
Figure 3A,B, based on fluorescence imaging to visualize
the tumor cells and the corresponding H&E images,
ROIs within the SARIFA-positive and SARIFA-
negative areas were chosen for multiplex profiling.
Sequencing libraries were generated as described
previously [23] according to NanoString’s GeoMx-
NGS Readout Library Prep instructions (NanoString
Technologies, Inc, Seattle, WA, USA) and sequenced
on an Illumina NovaSeq (Illumina Inc, San Diego,
CA, USA).
Immunohistochemical protein expression of
differentially expressed genes in DSP analysis and of
proteins associated with fatty acid metabolism,
hypoxia, and stem cell features
The immunohistochemical expression of FABP4,
CD36, CD44, carbonic anhydrase IX, CD68, and Ki67
Figure 1. H&E images of SARIFA-positive and SARIFA-negative cases: SARIFA-positive cases (A, C, E: scale bar = 200 μm; B, D, F: scale
bar = 50 μm) with tumor cells directly adjacent to local tissue, such as adipocytes (A–D) or smooth muscle in muscularis propria (E, F), with-
out a stromal reaction. SARIFA-negative case at the invasion front (G: scale bar = 200 μm; H: scale bar = 50 μm).
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obtained from 30 SARIFA-positive and 30 SARIFA-
negative cases was analyzed on 2 μm whole-slide
sections using the primary antibodies listed in supple-
mentary material, Table S1. Staining was performed on
the BOND Rx platform using the BOND Polymer
Refine Detection kit (Leica Biosystems, Nussloch,
Germany). Adequate controls were used for quality con-
trol during staining (see supplementary material,
Table S1). The staining was assessed separately for the
IF and tumor center (TC). For CD36, CD44, and car-
bonic anhydrase IX, the staining was evaluated using
the seven-tier semi-quantitative scoring system (immu-
noreactive score, IRS) proposed by Remmele and
Stegner [24] while taking into account staining intensity
and the percentage of positive tumor cells. For FABP4
and Ki67, the percentage of tumor cells positive was
assessed. Finally, the abundance of macrophages was
assessed through CD68 staining.
Statistical analyses
Chi-squared tests were used for hypothesis testing of dif-
ferences between relative frequencies. Continuous vari-
ables were compared using the Wilcoxon rank-sum
test, while correlations were calculated using the Spear-
man test. Kaplan–Meier estimates of survival rates were
compared using log-rank tests, and relative risks were
estimated by hazard ratios (HRs) obtained fromCox pro-
portional hazard models. Because overall patient sur-
vival was chosen as the study endpoint, an additional
comparison of survival curves was performed using the
Gehan–Breslow–Wilcoxon (GBW) test, as this gives
more weight to early events that are more likely to be
cancer-specific. Kappa statistics were used as a measure
of inter-observer agreement [25]. Statistical analyses
were performed using SPSS version 24 (IBM Corp.,
Armonk, NY, USA) and R version 4.0.3. Exploratory
significance levels (two-tailed) of 5% were used for
hypothesis testing. The DSP analysis was conducted
using GeoMx Analysis Suite Version 2.2.0.111
(NanoString Technologies, Inc).
Results
For Collection A, the mean age of the patients was 70.5
(range 30.0–95.0) years and the median follow-up time
was 56.0 (range 44.8–67.2) months. In total, 49% of
the patients died during the follow-up period. Detailed
clinicopathological characteristics are summarized in
Table 1. Overall, 24 (15%) cases were classified as
SARIFA-positive, and 136 (85%) were deemed
SARIFA-negative.
For Collection B, the mean age of the 320 patients at
the time of diagnosis was 69.0 (range 36.0–91.0) years
and the mean follow-up time was 62.0 (range 49.6–
74.4) months. Of the 320 patients, 54% died during the
follow-up period. Detailed clinicopathological charac-
teristics are provided in Table 2. Overall, 72 (22.5%)
tumors were classified as SARIFA-positive, while
248 (77.5%) were classified as SARIFA-negative.
SARIFA presents high inter-observer concordance
The first (FA), third (TA), and last author (LA)
independently assessed all the tumors included in this
study.
For Collection A, the overall kappa value obtained by
all three observers was 0.738 (FA and TA: 0.727; FA
and LA: 0.860; TA and LA: 0.636). For Collection B,
the overall kappa value obtained by all three observers
was 0.775 (FA and TA: 0.839; FA and LA: 0.763; TA
and LA: 0.721).
SARIFA and clinicopathological characteristics
The SARIFA-positive tumors were associated with sev-
eral clinicopathological factors in both collections. An
overview of this is presented in Tables 1 and 2 for Col-
lection A and B, respectively. In both collections,
SARIFA-positive tumors were associated with an
advanced T-stage (p < 0.01 for each), distant metastases
(p < 0.01 for each), and lymphovascular invasion
(p < 0.05 for each). Additionally, in Collection B, the
SARIFA-positive tumors were more frequently found
to present positive lymph nodes (p < 0.01) and vascular
invasion (p = 0.018). Further, no association with the
molecular TCGA subtypes could be seen in Collection
A or B (p = 0.218 and 0.225, respectively). As the inter-
action between adipose tissues and tumor cells has pri-
marily been studied in the context of obesity research,
we determined the relationship between SARIFA and
patients’ body mass index (BMI) in a subgroup of
60 cases (30 SARIFA-positive and -negative cases
each). Here, SARIFA was associated with a lower BMI
(median: 25 kg/m2) compared with non-SARIFA
patients (median: 27 kg/m2) (p = 0.038).
SARIFA and survival
For Collection A, patients who presented with SARIFA-
positive tumors had a significantly lower OS (plog
rank = 0.014, Figure 2A; pGBW = 0.165). SARIFA-pos-
itive patients had a median survival of 20.0 (11.0–29.0)
months as opposed to 44.0 (17.7–70.3) months for
SARIFA-negative cases. During the study period, 75%
of the patients who had SARIFA-positive tumors died,
whereas this was the case for 45% of the SARIFA-
negative patients.
For Collection B, patients with SARIFA-positive
tumors had a significantly lower OS (plog rank
+GBW < 0.001, Figure 2B). The SARIFA-positive cases
showed a median survival of 15.0 (6.5–23.5) months,
whereas patients with SARIFA-negative tumors had a
median survival of 41.0 (21.8–60.2) months. During
the study period, 69% of the patients who presented with
SARIFA-positive tumors died, whereas this was the case
for 50% of the SARIFA-negative patients.
Additionally, SARIFA positivity emerged as an inde-
pendent negative prognostic factor (HR 1.638, 95% CI
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1.153–2.326, p = 0.006) for OS in Cox regression ana-
lyses, which were adjusted according to the known prog-
nostic parameters (age, pT, pN, grading, and
lymphovascular and vascular invasion). The results of
these analyses are summarized in supplementary mate-
rial, Table S2.
Subgroup analysis
The subgroup analysis indicated the existence of a nega-
tive prognostic effect of SARIFA in primarily resected
(HR 1.866, 95% CI 1.350–2.581, p < 0.001) and CTx
patients (HR 2.003, 95% CI 1.145–3.506, p = 0.015).
As shown in supplementarymaterial, Table S3, SARIFA
is a prognostic factor for intestinal or non-intestinal Lau-
rén subtypes. The negative prognostic effect of SARIFA
can especially be seen in non-proximal tumor localiza-
tion. Regarding the pT stage, only advanced-stage
(pT3/4) SARIFA-positive patients showed a worse OS
(HR 1.618, 95% CI 1.200–2.180, p = 0.002), whereas
no differences in terms of survival could be observed
during the early stages (pT1/2) (HR 1.201, 95% CI
0.431–3.344, p = 0.726). Regarding the subgroups of
TCGA, SARIFA was found to be a negative prognostic
variable, especially in CIN (HR 1.756, 95% CI 1.106–
2.788, p = 0.017) and non-classifiable tumors (HR
2.460, 95% CI 1.436–4.216, p = 0.001. Detailed infor-
mation about this may be found in supplementary mate-
rial, Table S3.
Differentially expressed genes identified using DSP
Using DSP technology, we identified genes that were
significantly upregulated at the IF in SARIFA-positive
cases compared with SARIFA-negative cases, as shown
in Figure 3C. The most interesting upregulated genes in
SARIFA-positive cases at the IF included COL15A1
(p = 2.3569E-05), FABP2 (p = 0.000226326), FABP4
(p = 0.000763128), and FGB (p = 0.001792231). Fig-
ure 3 shows the differential expression of COL15A1
(Figure 3D) and FABP4 (Figure 3E) with the lowest
expression in the SARIFA-negative areas at the
IF. FAPB4 expression increases toward SARIFA-posi-
tive centers and again toward SARIFA-positive IFs.
The expression of COL15A1, FABP2, FABP4, and
FGB in the SARIFA-positive and SARIFA-negative
areas is demonstrated in Figure 3F.
In pathway analyses, the most upregulated genes in
the SARIFA-positive cases were found to be those asso-
ciated with triglyceride catabolism, endogenous sterols,
collagen chain trimerization, and fibrin clot formation.
Immunohistochemical detection of the protein
products of differentially expressed genes in DSP
analysis, and of proteins associated with hypoxia and
stem cell features
We wanted to confirm the differential expression of
FABP4, which was identified using DSP analysis, at
the protein level. FABP4 was almost exclusively
expressed in the SARIFA areas, whereas it was totally
absent in the TC, or in non-SARIFA cases at the IF or
TC (IF SARIFA versus non-SARIFA p < 0.001;
Figure 4A). Cancer cells acquire exogenous fatty acids
through cell-surface acid translocase, which is also
called CD36 [26,27]. CD36 was significantly upregu-
lated at the IF (p < 0.001) in SARIFA cases and was
almost absent or present at extremely low expression at
the TC and in non-SARIFA cases (Figure 4B). To assess
the number of tumor-associated macrophages (TAMs),
we immunostained for CD68. We observed that the
number of CD68+ cells increased at the IF (p = 0.019)
and in the TC (p = 0.060) in SARIFA cases compared
with SARIFA-negative tumors (Figure 4F).
To verify whether hypoxia plays a role with regard to
SARIFA, we assessed the expression of carbonic anhy-
drase IX. As shown in Figure 4G, no difference between
SARIFA and non-SARIFA cases was observed. In
Figure 4H, the expression of CD44 (a marker of stem
cell features) is shown. Expression of CD44 was signif-
icantly lower at the IF in SARIFA cases (p < 0.001) and
Figure 2. Discrimination of patient survival based on SARIFA status. The Kaplan–Meier curves of patients with SARIFA-positive and SARIFA-
negative tumors are shown. (A) Collection A (n = 160); (B) Collection B (n = 320). P value of log-rank test.
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TC (p = 0.001). Based on the proliferation-associated
marker Ki67, no difference was seen between the SAR-
IFA and non-SARIFA cases with regard to proliferation
activity (Figure 4I).
The expression of FABP4 at the IF showed a signifi-
cant inverse correlation with CD44 at the IF
(ρ = 0.446, p < 0.001) and in the TC (ρ = 0.476,
p < 0.001). FABP4 IF was found to be positively
Figure 3. Transcriptome analysis using DSP. (A, B) H&E slide of a TMA core of a SARIFA-positive tumor (A) and serial fluorescence image visu-
alizing the tumor cells in the SARIFA-area. Based on fluorescence imaging, ROIs were chosen for multiplex profiling (B). (C) Volcano plot
showing differentially expressed genes between SARIFA-positive and SARIFA-negative cases at the IF in DSP analysis. (D, E) COL151A
(D) and FABP4 (E) are significantly differentially expressed in SARIFA-negative, and SARIFA-positive TC and SARIFA-positive IF, showing
the highest expression in tumor cells at the IF in SARIFA cases. (F) Heatmap demonstrating the expression (digital counts) of COL15A1, FABP2,
FABP4, and FGB in all analyzed cases of non-SARIFA cases at the IF, and SARIFA cases in the TC and at the IF.
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Figure 4. Immunohistochemical protein expression of differentially expressed genes in DSP analysis and of proteins associated with hypoxia
and stem cell features. (A–C, F–I) Boxplots showing expression of FABP4 (A) and CD36 (B); BMI (C); (F) number of CD68+ cells; expression of
carbonic anhydrase IX (G), CD44 (H), and Ki67 (I); and examples of immunohistochemical staining. (D, E) Correlation matrix of the proteins at
the IF and the TC.
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correlated with the amount of CD68+ cells at the IF
(ρ = 0.316, p = 0.019) or in the TC (ρ = 0.388,
p = 0.003) and with CD36 expression at the IF
(ρ = 0.535, p < 0.001) (Figure 4D,E).
Discussion
So far, only a few prognostic and therapeutic biomarkers
have been identified for gastric cancer. To date, the most
important therapeutic marker in gastric carcinoma is
HER2 overexpression [28]. In addition, MSI status and
high PD-L1 expression are independent positive prog-
nostic factors in gastric carcinoma [14,29,30], while
aberrant E-cadherin expression is considered an unfa-
vorable prognostic factor, and even a negative predictive
factor for chemotherapy response [31]. Additionally,
MET amplification and overexpression are thought to
play a crucial role in gastric carcinogenesis, but this is
yet to be found as a predictive factor for the response
to anti-MET antibodies [14]. In this study, we present
SARIFA as a new histological prognostic biomarker in
gastric cancer that is easy to assess during routine
diagnostic assessment. When evaluating SARIFA,
there is no need for additional immunohistochemical
staining or complicated evaluation schemes, such as
those used for the evaluation of protein-based TCGA
classification [21,22], tumor budding, the TSR [10–12],
or the aforementioned prognostic biomarkers.
In addition, the criteria for SARIFA positivity are
defined simply, which is reflected in the considerably
low inter-observer variability with kappa values of 0.74
(Collection A) and 0.78 (Collection B) across all three
observers. The presence of a single tumor cell next to
inconspicuous adipocytes without the surrounding stroma
is sufficient for the identification of SARIFA positivity.
SARIFA positivity was found to be a significant prog-
nostic factor in both collections and emerged as an inde-
pendent negative prognostic factor for overall survival in
Collection B. As the majority of SARIFA cases are in
advanced T-stage (90%), SARIFA by its nature is
mainly a prognostic marker in already advanced cases.
In summary, SARIFA combines a high degree of repro-
ducibility, low additional effort, and high clinical rele-
vance. Recently, Wulczyn et al [32] identified a
morphologically similar phenomenon in colon carci-
noma using a deep learning system.
To provide hints with regard to the underlying tumor-
promoting mechanisms associated with SARIFA positiv-
ity, we conducted DSP. Among the most upregulated
pathways at the IF in SARIFA-positive cases, compared
with the negative cases, were those of collagen chain tri-
merization and fibrin clot formation. COL15A1 was
highly differentially expressed when comparing
SARIFA-positive and SARIFA-negative cases. In the
positive cases, its expression was also higher at the
periphery than in the tumor’s center. At first glance, this
seems contradictory, as SARIFA-positive cases do not
induce a stromal reaction and are characterized by the
absence of fibrous stroma between adipocytes and tumor.
COL15A1 encodes the alpha chain of type XV collagen,
which represents one component of the basement
membrane (BM) and is thought to function as an
adhering component between the BM and the surround-
ing matrix [33]. Karppinen et al [34] detected collagen
XV in the tumor stroma during late stages of tumor pro-
gression in squamous cell carcinoma. In our DSP analy-
sis, only the expression of tumor cells was assessed and
not explicitly of the stroma. Thus, the high expression in
the stroma is not an explanation for COL15A1 expression
in the tumor cells of SARIFA-positive cases. One could
speculate that COL15A1 is highly expressed because of
the synthesis of a non-functional protein, resulting in
inadequate collagen synthesis. But this is highly specula-
tive and needs to be investigated in further studies.
SARIFA-positive cases were associated with an increased
number of CD68-positivemacrophages. TAMs can polar-
ize toward M2 macrophages that enhance angiogenesis,
tumor invasion, and immune suppression [35,36]. It is
therefore probable that macrophages play a role in pre-
venting the tumor glands from being entrapped by desmo-
plastic fibers and induce a reduced response of the
immune system in SARIFA tumors. However, the charac-
teristics of TAMs and the polarization between M1 and
M2 macrophages that are known so far are based on
in vitro experiments and cannot be transferred without
limitations in vivo. The exact mechanisms that lead to this
phenomenon and the role of TAMs, which seem to have a
great heterogeneity and comprehensive functions, remain
to be elucidated [37].
Interestingly, other pathways that were significantly
upregulated in SARIFA-positive cases at the IF were
those of triglyceride catabolism and endogenous sterols.
Certain studies in the context of obesity research have
investigated the mechanisms of tumor-associated adipo-
cytes using cell culture experiments [16,26,38]. Wen
et al [39] report that colon cancer cells uptake fatty acids
secreted by adipocytes and that adipocytes activate
autophagy to support cancer cell survival by altering
homeostasis and cellular metabolism in cancer cells.
Among the most differentially expressed genes were
fatty acid-binding proteins 2 and 4 (FABP2 and FABP4).
Fatty acid-binding proteins (FABPs) facilitate fatty acid
transport to different cell organelles [40]. This seems to
be an interesting starting point for further investigations
to explain the underlying concepts of SARIFA and its
association with adverse prognosis and characteristics.
To confirm the differential expression of FABP4 at
the protein level, we used immunohistochemistry. We
found that FABP4 was expressed almost exclusively in
the tumor cells of SARIFA areas, whereas no expression
was found in the TC or at the IF of SARIFA-positive and
SARIFA-negative cases. Our finding regarding FABP4
expression in SARIFA areas supports the hypothesis that
tumor cells gain energy through tumor fatty acid oxida-
tion [41]. In addition, higher expression of CD36, which
enables tumor cells to take up free fatty acids [26,27],
was observed in the SARIFA areas. It was also observed
that CD36-positive tumor cells represent a metastasis-
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initiating cell population [42,43]. Thus, fatty acid
oxidation provides an efficient energy source for the
tumor [44]. The inhibition of this pathway could be an
attractive therapeutic option. In this respect, the transport
of acyl-CoAs into mitochondria by carnitine palmitoyl
transferase 1 (CPT1) represents a potential target [45].
The interaction between adipocytes and tumor
cells has been studied mainly in obesity research to
further address the questions of why obese persons
have an increased incidence of cancer with a poorer
prognosis [16,38]. However, we did not observe an asso-
ciation between SARIFA positivity and higher BMI; on
the contrary, SARIFA was even associated with lower
BMI in patients (Figure 4C). Thus, obesity does not
appear to be the trigger for tumor progression here.
Interestingly, the tumor cells also did not appear to be
affected by hypoxia, as indicated by the low expression
of the hypoxia marker carbonic anhydrase IX. Further,
stem cell features also do not seem to play a role in tumor
progression, and there even seems to be a lower expres-
sion of the stem cell marker CD44 in SARIFA
cases [46–49]. Rather, the tumor cells appear to be able
to proliferate unimpeded and invade the tissue. In doing
so, they benefit from their contact with adipocytes. It is
possible that tumor-associated macrophages induce a
reduced host tissue response. Thus, the term ‘stroma
areactive’ describes the observed biological process
quite well. The indications of SARIFA being the mor-
phological correlate of a certain tumor biology implicate
their possible role as a predictive marker for a therapy
targeting TAMs or overcoming the therapy resistance
created by tumor-associated fat [16,35]. In this regard,
our study has certain limitations, which are mainly
related to its retrospective nature. Our study has to be
considered an exploratory analysis, and the results have
to be validated using independent prospective cohorts.
This study presents SARIFA (Stroma Areactive
Invasion Front Areas) as an extremely promising
histomorphology-based prognostic factor that is related
to tumor-promoting adipocytes in gastric cancer. Further
studies will verify whether the results of this retrospec-
tive, single-center study can be confirmed and whether
SARIFA can serve as a universal prognostic indicator
for solid cancers.
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